354 related articles for article (PubMed ID: 18483388)
21. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
Yan XD; Li M; Yuan Y; Mao N; Pan LY
Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060
[TBL] [Abstract][Full Text] [Related]
22. Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems.
van Vlerken LE; Duan Z; Little SR; Seiden MV; Amiji MM
AAPS J; 2010 Jun; 12(2):171-80. PubMed ID: 20143195
[TBL] [Abstract][Full Text] [Related]
23. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo.
Zhang XY; Chen J; Zheng YF; Gao XL; Kang Y; Liu JC; Cheng MJ; Sun H; Xu CJ
Cancer Res; 2009 Aug; 69(16):6506-14. PubMed ID: 19638590
[TBL] [Abstract][Full Text] [Related]
24. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.
Bardella C; Dettori D; Olivero M; Coltella N; Mazzone M; Di Renzo MF
Clin Cancer Res; 2007 Apr; 13(7):2191-8. PubMed ID: 17404103
[TBL] [Abstract][Full Text] [Related]
25. In vitro cytotoxic activity of cationic paclitaxel nanoparticles on MDR-3T3 cells.
Niu G; Castro CH; Nguyen N; Sullivan SM; Hughes JA
J Drug Target; 2010 Jul; 18(6):468-76. PubMed ID: 20059301
[TBL] [Abstract][Full Text] [Related]
26. Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles.
Wang J; Tao X; Zhang Y; Wei D; Ren Y
Biomaterials; 2010 May; 31(15):4426-33. PubMed ID: 20188412
[TBL] [Abstract][Full Text] [Related]
27. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors.
Koziara JM; Whisman TR; Tseng MT; Mumper RJ
J Control Release; 2006 May; 112(3):312-9. PubMed ID: 16626835
[TBL] [Abstract][Full Text] [Related]
28. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
Auzenne E; Donato NJ; Li C; Leroux E; Price RE; Farquhar D; Klostergaard J
Clin Cancer Res; 2002 Feb; 8(2):573-81. PubMed ID: 11839679
[TBL] [Abstract][Full Text] [Related]
29. Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance.
Sarisozen C; Vural I; Levchenko T; Hincal AA; Torchilin VP
Drug Deliv; 2012 Nov; 19(8):363-70. PubMed ID: 23030458
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of antiproliferative effect of cis-diamminedichloroplatinum(II) by clomiphene and tamoxifen in human ovarian cancer cells.
Kikuchi Y; Hirata J; Kita T; Imaizumi E; Tode T; Nagata I
Gynecol Oncol; 1993 Jun; 49(3):365-72. PubMed ID: 8314539
[TBL] [Abstract][Full Text] [Related]
31. Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs.
Park EK; Lee SB; Lee YM
Biomaterials; 2005 Mar; 26(9):1053-61. PubMed ID: 15369694
[TBL] [Abstract][Full Text] [Related]
32. Enhancement in anti-proliferative effects of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles.
Deshpande D; Devalapally H; Amiji M
Pharm Res; 2008 Aug; 25(8):1936-47. PubMed ID: 18480968
[TBL] [Abstract][Full Text] [Related]
33. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy.
Sato S; Itamochi H; Kigawa J; Oishi T; Shimada M; Sato S; Naniwa J; Uegaki K; Nonaka M; Terakawa N
Cancer Sci; 2009 Mar; 100(3):546-51. PubMed ID: 19154404
[TBL] [Abstract][Full Text] [Related]
34. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.
Bai F; Wang C; Lu Q; Zhao M; Ban FQ; Yu DH; Guan YY; Luan X; Liu YR; Chen HZ; Fang C
Biomaterials; 2013 Aug; 34(26):6163-74. PubMed ID: 23706689
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of amphiphilic beta-cyclodextrin nanoparticles for paclitaxel delivery.
Bilensoy E; Gürkaynak O; Doğan AL; Hincal AA
Int J Pharm; 2008 Jan; 347(1-2):163-70. PubMed ID: 17689901
[TBL] [Abstract][Full Text] [Related]
36. In vivo efficacy of paclitaxel-loaded injectable in situ-forming gel against subcutaneous tumor growth.
Lee JY; Kim KS; Kang YM; Kim ES; Hwang SJ; Lee HB; Min BH; Kim JH; Kim MS
Int J Pharm; 2010 Jun; 392(1-2):51-6. PubMed ID: 20298770
[TBL] [Abstract][Full Text] [Related]
37. Decoration of polymeric micelles with cancer-specific peptide ligands for active targeting of paclitaxel.
Shahin M; Ahmed S; Kaur K; Lavasanifar A
Biomaterials; 2011 Aug; 32(22):5123-33. PubMed ID: 21501865
[TBL] [Abstract][Full Text] [Related]
38. PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells.
Sarisozen C; Vural I; Levchenko T; Hincal AA; Torchilin VP
Drug Deliv; 2012 May; 19(4):169-76. PubMed ID: 22506922
[TBL] [Abstract][Full Text] [Related]
39. Conjugation of arginine-glycine-aspartic acid peptides to poly(ethylene oxide)-b-poly(epsilon-caprolactone) micelles for enhanced intracellular drug delivery to metastatic tumor cells.
Xiong XB; Mahmud A; Uludağ H; Lavasanifar A
Biomacromolecules; 2007 Mar; 8(3):874-84. PubMed ID: 17315946
[TBL] [Abstract][Full Text] [Related]
40. Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer.
Vergara D; Bellomo C; Zhang X; Vergaro V; Tinelli A; Lorusso V; Rinaldi R; Lvov YM; Leporatti S; Maffia M
Nanomedicine; 2012 Aug; 8(6):891-9. PubMed ID: 22100754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
